Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor (Q45263919)

11 December 2017

Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor (English)

1 reference

11 December 2017

1 reference

6

Michel Komajda

1 reference

11 December 2017

3

Kenneth Dickstein

1 reference

11 December 2017

Marvin A Konstam

1

1 reference

11 December 2017

Philip A Poole-Wilson

2

1 reference

11 December 2017

Helmut Drexler

4

1 reference

11 December 2017

Steven J Justice

5

1 reference

11 December 2017

William Malbecq

7

1 reference

11 December 2017

Felipe A Martinez

8

1 reference

11 December 2017

James D Neaton

9

1 reference

11 December 2017

Gunter A J Riegger

10

1 reference

11 December 2017

Soneil Guptha

11

1 reference

11 December 2017

language of work or name

1 reference

2 September 2008

1 reference

European Journal of Heart Failure

11 December 2017

1 reference

11 December 2017

10

1 reference

11 December 2017

9

1 reference

11 December 2017

899-906

1 reference

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

11 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Current guidelines for treatment of heart failure: 2006 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Mechanisms for the clinical benefits of angiotensin II receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Angiotensin receptors and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

Clinical safety and tolerability of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.07.004

10.1016/J.EJHEART.2008.07.004

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference